Researchers intended to see how the treatments will affect metastatic colorectal cancer patients with microsatellite stable tumors.
Here’s what you should know.
1. The companies are collaborating on a phase 1/2 study.
2. The results will determine recommended dose regimens. Researchers are hoping the treatments produce preliminary anti-tumor activity.
3. The companies want to begin the study in late 2017.
4. The companies will use the study results to propel further research.
More articles on gastroenterology:
Craig Campbell to hold ‘Cornhole Challenge’ for Fight Colorectal Cancer — 3 insights
GI leader to know: Dr. Adrienne Scheich of Ann & Robert H. Lurie Children’s Hospital
American Cancer Society Nutrition and Physical Activity guidelines increases colon cancer survival rates — 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
